Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
13.76
+0.43 (3.23%)
Oct 28, 2025, 4:00 PM EDT - Market closed
Pharming Group Stock Forecast
Stock Price Forecast
The 3 analysts that cover Pharming Group stock have a consensus rating of "Strong Buy" and an average price target of $30, which forecasts a 118.02% increase in the stock price over the next year. The lowest target is $14 and the highest is $39.
Price Target: $30 (+118.02%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
The average analyst rating for Pharming Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +168.90% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +168.90% | Mar 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $39 | Buy | Maintains | $30 → $39 | +183.43% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +168.90% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +168.90% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
349.81M
from 297.20M
Increased by 17.70%
Revenue Next Year
392.66M
from 349.81M
Increased by 12.25%
EPS This Year
0.04
from -0.02
EPS Next Year
0.06
from 0.04
Increased by 67.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 378.2M | 434.0M | |||
| Avg | 349.8M | 392.7M | |||
| Low | 305.8M | 336.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.3% | 24.1% | |||
| Avg | 17.7% | 12.2% | |||
| Low | 2.9% | -3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.16 | 0.17 | |||
| Avg | 0.04 | 0.06 | |||
| Low | -0.02 | -0.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 352.6% | |||
| Avg | - | 67.9% | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.